Anti-IL-7R neutralizing monoclonal antibodies have demonstrated therapeutic effect in preclinical research of autoimmune diseases, such as autoimmune diabetes [130] and arthritis [131]. The gene discussed is IL7R; the disease is autoimmune disease.